AI Article Synopsis

  • The study aims to define hepatocellular malignant neoplasm, NOS (HEMNOS), as a new category of pediatric liver tumors that don't fit typical classifications of hepatoblastoma (HB) or hepatocellular carcinoma (HCC).
  • A retrospective analysis of 11 pediatric patients revealed they mostly had advanced-stage tumors, with many showing overlapping characteristics of both HB and HCC, and a high serum alpha-fetoprotein level at diagnosis.
  • Despite the high-risk features, all patients achieved remission after receiving chemotherapy and complete tumor resection, suggesting that HEMNOS, though complex, has a positive treatment outcome.

Article Abstract

Aims: The primary aim of this study is to characterize hepatocellular malignant neoplasm, NOS (HEMNOS), a new provisional entity describing a subset of paediatric hepatocellular tumours, which have histological features of neither typical hepatoblastoma (HB) nor hepatocellular carcinoma (HCC).

Methods And Results: The clinicopathological features of 11 patients with HEMNOS were analysed retrospectively. The median age and serum alpha-fetoprotein level at diagnosis was 7 years and 182 000 ng/ml, respectively. Ten patients presented with pretreatment extent of disease (PRETEXT) stages III/IV multifocal tumours, eight with major vascular involvement, three with lung metastases and three with extrahepatic extension. The original pathology diagnoses were: HB in seven patients, HCC in two and HEMNOS in two. Our pathology review of pre-chemotherapy specimens showed that six tumours had equivocal/overlapping histological features of HB and HCC, four had predominant HB histology along with focal HCC-like histology and one had HB histology. Seven of nine post-chemotherapy resection specimens showed predominant HCC-like histology. Beta-catenin, glypican 3 and spalt-like transcription factor 4 immunostaining showed that all the tumours had a mixed HB/HCC immunophenotype. Telomerase reverse transcriptase immunostaining showed nuclear staining in nine of the 11 tumours. All patients received chemotherapy and achieved gross total primary tumour resection. Nine of the 11 patients were treated with established HB chemotherapy regimens. After a median follow-up of 6.1 years (range: 1.2-11.8 years), all patients were in remission.

Conclusions: HEMNOS is a subtype of HB with focal HCC-like histology, a high-risk clinical profile but favourable outcome following chemotherapy and complete tumour resection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521842PMC
http://dx.doi.org/10.1111/his.13297DOI Listing

Publication Analysis

Top Keywords

hcc-like histology
12
hepatocellular malignant
8
malignant neoplasm
8
histological features
8
focal hcc-like
8
tumour resection
8
patients
6
tumours
5
histology
5
hepatocellular
4

Similar Publications

(Lam.) B. Zepernick & Timler alkaloidal extract exerts hepatoprotective effects in rats with a CCl/olive oil-induced hepatocellular carcinoma-like phenotype.

J Taibah Univ Med Sci

August 2024

Department of Medical Laboratory Science, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.

Objective: This study assessed the prophylactic anti-HCC effects of a combined stem and root alkaloidal extract of  () (SRAEZZ) in rats with a CCl/olive oil-induced HCC-like phenotype.

Methods: SRAEZZ was prepared from dried stems and roots of in a 1:1 proportion and chemically characterized. A total of 30 healthy male Wistar rats (weighing 210-280 g) were randomly assigned to six groups (control, model, capecitabine, and SRAEZZ [50, 100, or 200 mg/kg]).

View Article and Find Full Text PDF

Background: Traditional herbal medicine practitioners in the Ashanti region of Ghana use the fruit peels of (L.) Osbeck () in preventive and curative treatment of many cancers including liver cancer. This ethnobotanical claim remains to be verified scientifically.

View Article and Find Full Text PDF

Background: There is considerable evidence that microRNAs (miRNAs) regulate several key tumor-associated genes/pathways and may themselves have a dual regulatory function either as tumor suppressors or oncogenic miRNA, depending on the tumor type. MicroRNA-590-3p (miR-590-3p) is a small non-coding RNA involved in the initiation and progression of numerous tumors. However, its expression pattern and biological role in hepatocellular carcinoma (HCC) are controversial.

View Article and Find Full Text PDF

Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.

Hepatology

January 2023

Department of Pathology , Graduate School of Medical Science , Brain Korea 21 Project , Yonsei University College of Medicine, Seoul , Republic of Korea.

Background And Aims: Primary liver cancers (LCs), including HCC and intrahepatic cholangiocarcinoma (iCCA), are derived from a common developmental lineage, conferring a molecular spectrum between them. To elucidate the molecular spectrum, we performed an integrative analysis of transcriptome profiles associated with patients' radiopathologic features.

Approach And Results: We identified four LC subtypes (LC1-LC4) from RNA-sequencing profiles, revealing intermediate subtypes between HCC and iCCA.

View Article and Find Full Text PDF

Hepatoid Adenocarcinoma of the Lung.

Technol Cancer Res Treat

March 2022

Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), P.R. China.

Hepatoid adenocarcinoma of the lung (HAL) is an comparatively rare malignant tumor originating from the lung with shorter survival. HAL morphologically and pathologically exhibits hepatocellular carcinoma (HCC)-like characteristics, while its clinical features resemble pulmonary adenocarcinoma. High concentration of alpha-fetoprotein (AFP) is often detected in the serum of HAL patients with no hepatic occupying lesion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!